![]() |
市场调查报告书
商品编码
1521169
2024-2032 年依产品类型(瓣膜、心律调节器、植入式心律调节器、体外心律调节器等)、最终使用者(医院、诊所和心臟中心、门诊手术中心等)和地区分類的心臟假体装置市场报告Cardiac Prosthetic Devices Market Report by Product Type (Valves, Pacemakers, Implantable Pacemakers, External Pacemakers, and Others), End-User (Hospitals, Clinics and Cardiac Centers, Ambulatory Surgical Centers, and Others), and Region 2024-2032 |
IMARC Group年,全球心臟假体器械市场规模达67亿美元。紧凑型起搏器和免缝合瓣膜置换术的发展、微创(MI)手术的日益增长以及大众心血管疾病患病率的上升是推动该市场的一些主要因素。
心臟假体装置是指设计用于替代或辅助心臟正常功能的人造装置或植入物。它们用于治疗各种心臟疾病,例如心臟衰竭、瓣膜疾病或先天性心臟缺陷。它们大致可分为两种类型:人工心臟瓣膜和机械循环支撑装置。人工心臟瓣膜用于替换受损或患病的心臟瓣膜,恢復流经心臟的正常血流。另一方面,机械循环支撑装置用于辅助或替代心臟的泵血功能,通常用作移植的桥樑或作为不适合心臟移植的患者的长期解决方案。此外,它们由生物相容性材料製成,经过精心设计,可复製心臟的结构和功能,从而改善患者的心臟功能和生活品质。
该行业是由全球人口老化所推动的。随着人口持续老化,心血管疾病的发生率增加,导致对心臟假体装置的需求更高。此外,医疗技术和外科技术的不断进步提高了心血管疾病患者的生存率,这为这些设备创造了更大的患者库。同时,大众对心血管健康的认识不断提高以及治疗方案的可用性正在推动产品需求。此外,患者正在寻求及时的干预措施,包括使用心臟假体装置,以提高生活品质并延长生存期,这对市场产生了积极影响。其他因素,包括医疗保健行业的持续发展以及主要参与者进行的广泛研发(R&D)活动,也对市场产生积极影响。
心血管疾病的盛行率及其意识的提高
心血管疾病,包括冠状动脉疾病、心臟衰竭和瓣膜性心臟病,是全球发病率和死亡率的重要原因。此外,人们对心臟病、预防措施和治疗方案的认识不断提高,从而可以更早发现和诊断心血管疾病。诊断能力的提高,包括超音波心动图和心臟 MRI 等先进影像技术,有助于准确诊断和识别可能受益于心臟假体装置的患者。公众意识的提高和多种疾病盛行率的上升共同导致了产品需求的增加。随着越来越多的人在早期被诊断出患有心血管疾病,越来越多的患者可以从涉及心臟修復术的干预措施中受益。
落实优惠报销政策
报销在心臟假体装置的采用中发挥着至关重要的作用。政府医疗保健系统和私人保险提供者提供的优惠报销政策激励医疗保健提供者向患者提供这些设备和程序。这为市场成长创造了有利的环境,因为它减少了患者的经济障碍并促进了心臟假体设备的使用。此外,不断增加的疾病负担和医疗技术的进步正在增加全球的医疗保健支出。医疗保健支出的增加有助于提高心臟假体设备的可负担性和可及性,从而使有需要的患者能够更广泛地获得它们。除此之外,市场参与者正在建立伙伴关係、协作和分销网络,这是另一个成长诱导因素。
心臟手术技术和设备的持续技术创新
心臟外科技术的不断进步,如微创手术、机器人辅助手术和经导管介入治疗,扩大了治疗各种心臟疾病的范围。这些进步提高了产品的利用率,包括心臟瓣膜、心室辅助装置 (VAD) 和起搏器,因为它们在这些手术中发挥着至关重要的作用。科技的快速进步彻底改变了心臟假体设备的设计和功能。例如,经导管心臟瓣膜的发展使得微创瓣膜置换手术成为可能,减少了患者的创伤和恢復时间。此外,心律调节器和植入式心律转復除颤器 (ICD) 中无线连接、远端监控功能和先进感测器的整合改善了患者护理和结果,创造了积极的市场前景。
The global cardiac prosthetic devices market size reached US$ 6.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 12.3 Billion by 2032, exhibiting a growth rate (CAGR) of 6.8% during 2024-2032. The development of compact pacemakers and suture-less valve replacements, the growing inclination toward minimally invasive (MI) procedures, and the rising prevalence of cardiovascular disorders among the masses are some of the major factors propelling the market.
Cardiac prosthetic devices refer to artificial devices or implants designed to replace or assist the normal functioning of the heart. They are used in the treatment of various heart conditions, such as heart failure, valve disorders, or congenital heart defects. They can be broadly categorized into two types, artificial heart valves and mechanical circulatory support devices. Artificial heart valves are used to replace damaged or diseased heart valves, restoring normal blood flow through the heart. On the other hand, mechanical circulatory support devices are used to assist or replace the pumping function of the heart, often employed as a bridge to transplantation or as a long-term solution for patients ineligible for heart transplantation. Additionally, they are manufactured of biocompatible materials and are meticulously designed to replicate the structure and function of the heart, thereby improving the patient's cardiac function and quality of life.
The industry is driven by the aging global population. As the population continues to age, the incidence of cardiovascular diseases increases, leading to a higher demand for cardiac prosthetic devices. Additionally, continual advancements in medical technology and surgical techniques have improved the survival rates of patients with cardiovascular diseases, this is creating a larger patient pool for these devices. Along with this, the increasing awareness about cardiovascular health and the availability of treatment options among the masses is fueling the product demand. Also, patients are seeking timely interventions, including the use of cardiac prosthetic devices, to improve their quality of life and prolong survival, which is positively influencing the market. Other factors, including continual developments in the healthcare sector and extensive research and development (R&D) activities conducted by key players, are also positively influencing the market.
Increasing Prevalence of Cardiovascular Diseases and their Awareness
Cardiovascular diseases, including coronary artery disease, heart failure, and valvular heart diseases, are significant contributors to morbidity and mortality across the globe. Additionally, the increasing awareness about heart diseases, preventive measures, and the availability of treatment options has led to earlier detection and diagnosis of cardiovascular conditions. Improved diagnostic capabilities, including advanced imaging techniques, such as echocardiography and cardiac MRI, facilitate accurate diagnosis and identification of patients who may benefit from cardiac prosthetic devices. The combination of public awareness and the rising prevalence of numerous diseases has led to an increasing product demand. As more individuals are diagnosed with CVDs at an earlier stage, there is a growing pool of patients who could benefit from interventions involving cardiac prosthetics.
The Implementation of Favorable Reimbursement Policies
Reimbursement plays a vital role in the adoption of cardiac prosthetic devices. Favorable reimbursement policies offered by government healthcare systems and private insurance providers incentivize healthcare providers to offer these devices and procedures to their patients. This creates a conducive environment for market growth, as it reduces financial barriers for patients and promotes the use of cardiac prosthetic devices. In addition, the rising disease burden, and advances in medical technology are increasing healthcare expenditure across the globe. This higher healthcare spending is contributing to the affordability and accessibility of cardiac prosthetic devices, making them more widely available to patients in need. Besides this, market players are establishing partnerships, collaborations, and distribution networks, which are acting as another growth-inducing factor.
Continual Technological Innovations in Cardiac Surgery Techniques and Devices
Continuous advancements in cardiac surgical techniques, such as minimally invasive procedures, robotic-assisted surgeries, and transcatheter interventions, have expanded the scope of treating various cardiac conditions. These advancements have increased product utilization, including heart valves, ventricular assist devices (VADs), and pacemakers, as they play a crucial role in these procedures. Rapid advancements in technology have revolutionized the design and functionality of cardiac prosthetic devices. For instance, the development of transcatheter heart valves has enabled less invasive valve replacement procedures, reducing patient trauma and recovery time. Additionally, the integration of wireless connectivity, remote monitoring capabilities, and advanced sensors in pacemakers and implantable cardioverter-defibrillators (ICDs) has improved patient care and outcomes, creating a positive market outlook.
IMARC Group provides an analysis of the key trends in each segment of the global cardiac prosthetic devices report, along with forecasts at the global, regional, and country levels from 2024-2032. Our report has categorized the market based on product type and end-user.
Valves
Mechanical Valve
Tissue Valve
Stented Tissue Valve
Stentless Tissue Valve
Transcatheter Valve
Pacemakers
Implantable Pacemakers
Single-Chamber Battery Pacemaker
Dual-Chamber Battery Pacemaker
Triple-Chamber Battery Pacemaker
External Pacemakers
Others
Valves dominate the market
The report has provided a detailed breakup and analysis of the market based on the product type. This includes valves (mechanical valve, tissue valve, stented tissue valve, stentless tissue valve, and transcatheter valve), pacemakers, implantable pacemakers (single-chamber battery pacemaker, dual-chamber battery pacemaker, and triple-chamber battery pacemaker), external pacemakers, and others. According to the report, valves represented the largest segment.
Continual technological advancements in valve design and materials have improved the durability, functionality, and overall performance of devices, leading to greater acceptance and adoption. Additionally, the increasing focus on minimally invasive procedures and the development of transcatheter heart valve replacement techniques are positively influencing the demand for valve products.
Additionally, continuous advancements in medical technology have led to the development of innovative pacemaker devices with improved features and functionalities, including wireless connectivity and remote monitoring capabilities, which further drive market growth. Moreover, the rising prevalence of lifestyle-related diseases, such as obesity and diabetes, which are risk factors for heart ailments, is fueling the demand for pacemakers across the globe.
Hospitals, Clinics and Cardiac Centers
Ambulatory Surgical Centers
Others
Hospitals, clinics and cardiac centers hold the largest share in the market
A detailed breakup and analysis of the market based on the end-user has also been provided in the report. This includes hospitals, clinics and cardiac centers, ambulatory surgical centers, and others. According to the report, hospitals, clinics, and cardiac centers accounted for the largest market share.
The increasing usage of these devices in hospitals, clinics, and cardiac centers can be attributed to the continual advancements in medical technology and surgical techniques. The continuous development of innovative devices, such as artificial heart valves and implantable pacemakers, enables healthcare providers to offer improved treatment options to patients. Furthermore, various government initiatives and healthcare reforms aimed at enhancing cardiovascular care and improving patient outcomes also serve as major market drivers for the end-users in the industry.
On the contrary, ambulatory surgical centers (ASCs) as end-users in the cardiac offer numerous advantages, such as cost-effectiveness, convenience, and reduced hospital stays, which are particularly appealing to patients seeking cardiac procedures. These centers provide a suitable environment for minimally invasive surgeries and outpatient treatments, aligning with the growing trend towards value-based healthcare. Additionally, advancements in technology have made it feasible to perform complex cardiac procedures in ASCs, further fueling the market demand in this segment over the forecast period.
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
North America exhibits a clear dominance, accounting for the largest the cardiac prosthetic devices market share
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa.
The market in North America is driven by the increasing prevalence of cardiovascular diseases and the growing aging population. As heart-related conditions become more common, the need for devices such as heart valves, pacemakers, and implantable defibrillators is growing. Additionally, the healthcare system across the region focuses on quality healthcare delivery and reimbursement support for medical devices also plays a significant role in the growth of the market. Moreover, research and development efforts aimed at developing innovative and minimally invasive prosthetic devices are significantly supporting the market.
On the contrary, Asia Pacific is estimated to expand further in this domain in the coming years due to the aging population and changing lifestyles. In confluence with this, advancements in healthcare infrastructure and the rising disposable income in several countries within the Asia Pacific region have improved access to medical treatments and increased affordability. Furthermore, ongoing technological advancements and innovations in the field are driving the market in Asia Pacific.
The market is experiencing significant growth due to the continual advancements in medical technology and surgical procedures leading to the development of innovative and more efficient devices. Additionally, the integration of digital health technologies is creating opportunities for companies to offer remote monitoring solutions and personalized healthcare services, enhancing patient outcomes and increasing the overall value proposition of their products. Also, numerous companies are developing tailored solutions to address specific patient needs, this is gaining prominence across the globe. Moreover, the development of 3D printing technology has further facilitated the production of patient-specific devices, allowing for better fit and improved functionality. Additionally, top companies are investing in research and development to create customizable solutions and collaborate with healthcare professionals to understand patient requirements, which is influencing the market.
Abbott Laboratories
Biotronik
Boston Scientific Corporation
Edwards Lifesciences Corporation
Lepu Medical Technology Co. Ltd.
Medtronic Inc.
Meril Life Sciences Pvt. Ltd.
Siemens Healthcare GmbH
Sorin Group
St. Jude Medical Inc.
In September 2021, Abbott Laboratories announced that the company's Epic Plus and Epic Plus Supra Stented Tissue Valves have received FDA approval, expanding treatment options for patients with aortic or mitral valve dysfunction.
In January 2020, Medtronic Inc. announced that its Cobalt and Crome cardiac resynchronization therapy-defibrillators (CRT-D) and implanted cardioverter-defibrillators (ICD) received EU CE Mark certification, permitting their entry to the continent.
In June 2019, Biotronik announced the release of a new model of its well-known injectable heart monitor, BIOMONITOR. While being significantly smaller than the BIOMONITOR 2, the BIOMONITOR III provides a substantially crisper signal quality.